USFDA gives nod to Lupin generic psoriasis treatment solution
New Delhi: Pharma major Lupin Ltd said it has received final approval from the US health regulator for its generic version of Dovonex scalp solution used in the treatment of psoriasis of the scalp.
The approval by the US Food and Drug Administration (USFDA) to Lupin's calcipotriene topical solution is for the strength of 0.005 percent (scalp solution), the company said in a statement.
It is the generic equivalent of Dovonex scalp solution of Lep Pharmaceutical Products Ltd. It is used for topical treatment of chronic, moderately severe psoriasis of the scalp.
Citing IMS data, the company said Calcipotriene topical solution had annual sales of USD 5.9 million in the US till October this year.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd